The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
July 12th 2025
Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.
FDA Approves Drug Combination for Treating BRAF-positive Anaplastic Thyroid Cancer
May 7th 2018The FDA has approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.
Read More